P5‐122: A case of secondary organizing pneumonia caused by relapse of inflammation after COVID‐19 treatment with systemic corticosteroid and tocilizumab

• DOI: 10.1111/resp.14150_329
• Publication Date: 2021-11-20T04:03:12Z
• Authors: Yasumitsu Ueki; Daisuke Kinose; Shogo Okuda; Tsukasa Nakanishi; Ryo Kuroda; Tomoko Iriyama; Yoko Tsunoda; Akio Yamazaki; Satoru Kawashima; Ayano Sonoda; Tomohiro Hirata; Yasuki Uchida; Hiroaki Nakagawa; Makato Osawa; Masafumi Yamaguchi; Yasutaka Nakano
• Keywords: Clinical endpoint; Tocilizumab; Oxygen therapy; Oxygen Saturation

Intervention: Inhaled dry-powder beclomethasone 1200 mcg per day compared with placebo Primary Outcome: The primary endpoint is progression of disease severity defined by Á oxygen saturation drop < 94% and any one the following 3 treatment escalation steps: o initiation supplemental dexamethasone transfer to a higher-tier healthcare facility Sample Size: 190 arm Sampling Method: Participants randomized inhaled or placebo, in addition usual care, random sequence generator 1:1 ratio double blind manner Data Collection Interviewer administered questionnaire, measurement temperature using non-invasive methods, self-administered CCQ FLUPro questionnaire.